Gain Therapeutics (GANX) Current Assets (2020 - 2026)

Gain Therapeutics has reported Current Assets for 7 years, with the latest figure at $15.0 million in Q2 2026.

• On a quarterly basis, Current Assets rose 60.85% year-over-year to $15.0 million in Q2 2026; TTM through Jun 2026 was $15.0 million, a 60.85% increase from a year earlier, with the FY2025 full-year figure at $22.2 million, up 91.66% from the prior year.
• Current Assets was $15.0 million for Q2 2026 at Gain Therapeutics, down from $18.2 million in the prior quarter.
• The five-year high for Current Assets was $36.4 million in Q1 2022, with the low at $9.3 million in Q2 2025.
• Average Current Assets over 5 years is $17.7 million, with a median of $17.5 million recorded in 2023.
• The largest YoY upside for Current Assets was 91.66% in 2025 against a maximum downside of 49.8% in 2025.
• Over 5 years, Current Assets stood at $21.1 million in 2022, then decreased by 15.71% to $17.8 million in 2023, then plunged by 34.74% to $11.6 million in 2024, then jumped by 91.66% to $22.2 million in 2025, then slumped by 32.68% to $15.0 million in 2026.
• The last three Current Assets figures came in at $15.0 million (Q2 2026), $18.2 million (Q1 2026), and $22.2 million (Q4 2025), per Business Quant data.